Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $12.31, for a total value of $24,620.00. Following the sale, the president now owns 2,831,260 shares of the company’s stock, valued at approximately $34,852,810.60. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Songjiang Ma also recently made the following trade(s):

• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.74, for a total value of $23,480.00.
• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.14, for a total value of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total value of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.90, for a total value of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total value of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.43, for a total value of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total value of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total value of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total value of $21,440.00.

Gyre Therapeutics Trading Down 30.2 %

GYRE opened at $8.57 on Wednesday. The business’s 50 day moving average price is $11.29 and its 200 day moving average price is $12.25. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $19.00.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings results on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.03). Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%. The firm had revenue of $27.87 million for the quarter, compared to analyst estimates of $23.50 million.

Analysts Set New Price Targets

Separately, Noble Financial began coverage on Gyre Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating on the stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. FMR LLC acquired a new position in Gyre Therapeutics during the third quarter worth $47,000. Wells Fargo & Company MN raised its stake in shares of Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after acquiring an additional 913 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after acquiring an additional 1,996 shares in the last quarter. Barclays PLC raised its stake in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Gyre Therapeutics by 11.1% in the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock valued at $168,000 after acquiring an additional 1,389 shares in the last quarter. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.